Reviva Pharmaceuticals Holdings, Inc. Share Price Nasdaq
Equities
TZAC
US76152G1004
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 40.85M 3.4B |
---|---|---|---|---|---|
Net income 2024 * | -39M -3.24B | Net income 2025 * | -45M -3.74B | EV / Sales 2024 * | - |
Net cash position 2024 * | 8.8M 732M | Net cash position 2025 * | 1.2M 99.76M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.24
x | P/E ratio 2025 * |
-1.55
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.05% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 11/20/11 | |
Narayan Prabhu
DFI | Director of Finance/CFO | 53 | 14/20/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 14/20/14 | |
Les Funtleyder
BRD | Director/Board Member | 54 | 14/20/14 |
Founder | 59 | 11/20/11 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |